Abecarnil

Abecarnil

SCHEMBL5083743

COCc1c(C(=O)OC(C)C)ncc2[nH]c3ccc(OCc4ccccc4)cc3c12.c1ccc2c(c1)[nH]c1ncccc12

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 14/20 0.83
GABRG2 P18507 14/20 0.83
GABRB3 P28472 14/20 0.83
GABRA5 P31644 14/20 0.83
GABRA3 P34903 14/20 0.83
GABRA2 P47869 12/20 0.83
GABRP O00591 7/20 0.83
GABRD O14764 7/20 0.83
GABRB1 P18505 7/20 0.83
GABRB2 P47870 7/20 0.83
GABRA4 P48169 7/20 0.83
GABRE P78334 7/20 0.83
GABRA6 Q16445 7/20 0.83
GABRG1 Q8N1C3 7/20 0.83
GABRG3 Q99928 7/20 0.83
GABRQ Q9UN88 7/20 0.83
ALDH1A1 P00352 1/20 0.67
MAPT P10636 1/20 0.67
HPGD P15428 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Abecarnil SCHEMBL4311489 0.92 GABRA1 (0.85) GABRA1GABRG2GABRB3GABRA5GABRA3
Abecarnil SCHEMBL29716465 0.91 GABRA1 (1.00) GABRA1GABRG2GABRB3GABRA5GABRA3
Abecarnil SCHEMBL635373 0.91 GABRA1 (1.00) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL31623789 0.85 GABRA1 (0.85) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL9425899 0.84 GABRA1 (0.85) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL9425751 0.84 GABRA1 (0.85) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL8845290 0.84 GABRA1 (0.85) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL9426144 0.84 GABRA1 (0.85) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL8845900 0.84 GABRA1 (0.85) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL8845507 0.83 GABRA1 (0.84) GABRA1GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160367562-A1 USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF DOGS BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2016-12-22 US disclosed
US-9469611-B2 Use of dihydroimidazolones for the treatment of dogs BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2016-10-18 US disclosed
US-20150072983-A1 USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF DOGS BOEHRINGER INGELHEIM VETMED (DE) 2015-03-12 US disclosed
US-8962617-B2 Use of dihydroimidazolones for the treatment of dogs BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2015-02-24 US disclosed
US-8859540-B2 Use of dihydroimidazolones for the treatment of dogs BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2014-10-14 US disclosed
US-20130065898-A1 USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF DOGS RUNDFELDT CHRIS (DE) 2013-03-14 US disclosed
US-20080027057-A1 Use of dihydroimidazolones for the treatment of dogs RUNDFELDT CHRIS 2008-01-31 US disclosed
US-20050070537-A1 Use of dihydroimidazolones for the treatment of dogs BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2005-03-31 US disclosed